Prostat kanseri tanısında, serum prostatik asit fosfataz (PAP) ve prostat spesifik antijen (PSA) düzeyleri yanı sıra yeni bir parametre: siyalik asit

Abstract

-66- 7, SUMMARY It is of great importance to detect the prostat hyperplasia and prostat cancer cases concerning a large portion of the society, in early stages. Today, several biochemical parameters are used to determine and to follow up the cases with hyperplasia and cancer, In this study, serum prostatic acid phosphatase (PAP) and prostate specific antigen (PSA) levels were investigated in the control group composed of 20 healty men, ages ranging from 17 to 65; in 25 men with prostatic hyperplasia, ages ranging from 55 to 75; in 10, 9, 10 and 14 men with prostate cancer, their stages being A, B, C and D respectively, ages ranging from 55 to 75. Radio immuna assay (İÎÂ) methods were used to determine serum PAP levels and enzyme immuno assay methods were used to determine serum PSA levels. With these methods, serum PAP levels were found to be 1.39+0.66 ng/ol in the control group, 2.41±1.40 ng/ml in the hyperplasia graup and 1,39±1.07, 2.32±1.25, 9,96±8.2i, 36,S9±34.i8 ng/al in stages A, B, C and D respectively. Serum PSA levels were found to be 2.62+1.30 ng/ml in the control group, S.73±4,10 ng/ml in the hyperplasia group and 3,28±2.70, 19,33±13.29, 37.6±30,73, 186.3±83,2 ng/ml in stages A, B, C and D respectively. The difference between the serum levels of PSA In sancer stages B, C, D and the control group was ıtatîstlcally significant. On the other hand, serum PAP levels of proitate cancer cases exhibit a statistically significant difference from serum PAP levels of the control group only at stage D prostate cancer. According to these data, it is reasonable to say that P5A is a better tumor marker than-67- PAP. The difference between serum PAP and PSA levels in prostate hyperplasia cases and prostate cancer those of in stage A and B is statistically insignificant. This condition is chaotic in the detection of prostate hyperplasia and early stages of prostate cancer, The available data clearly reveal that a new parameter besides PAP and PSA is necessary to increase the efficiency in diagnosis. Serving this aim, serum sialic acid levels were investigated in the control group, prostate hyperplasia group and prostate cancer group to determine whether serum sialic acid levels are useful in diagnosis. The serum sialic acid levels determined by enzymatlc-colorimetric method were 65.75±5.59 mg/dl in the control group, 63,6±6.9 mg/dl in the hyperplasia group and 79.2819.09, 89.9B±7.D1, 92.11+12.43, 101.3+14.5 mg/dl in A, B, C and D stages respectively Df cancer group. The difference between serum sialic acid levels of the control group and the prostatic hyperplasia group was found to be statistically insignificant. However, it was demostrated that the serum sialic acid levels of cancer cases were statistically different from those of control and hyperplasia group. According to obtained data we can conclude that it is essential to determine serum sialic acid levels besides PAP and PSA in order to detect prostat cancer cases at the early stages.

-66- 7, SUMMARY It is of great importance to detect the prostat hyperplasia and prostat cancer cases concerning a large portion of the society, in early stages. Today, several biochemical parameters are used to determine and to follow up the cases with hyperplasia and cancer, In this study, serum prostatic acid phosphatase (PAP) and prostate specific antigen (PSA) levels were investigated in the control group composed of 20 healty men, ages ranging from 17 to 65; in 25 men with prostatic hyperplasia, ages ranging from 55 to 75; in 10, 9, 10 and 14 men with prostate cancer, their stages being A, B, C and D respectively, ages ranging from 55 to 75. Radio immuna assay (İÎÂ) methods were used to determine serum PAP levels and enzyme immuno assay methods were used to determine serum PSA levels. With these methods, serum PAP levels were found to be 1.39+0.66 ng/ol in the control group, 2.41±1.40 ng/ml in the hyperplasia graup and 1,39±1.07, 2.32±1.25, 9,96±8.2i, 36,S9±34.i8 ng/al in stages A, B, C and D respectively. Serum PSA levels were found to be 2.62+1.30 ng/ml in the control group, S.73±4,10 ng/ml in the hyperplasia group and 3,28±2.70, 19,33±13.29, 37.6±30,73, 186.3±83,2 ng/ml in stages A, B, C and D respectively. The difference between the serum levels of PSA In sancer stages B, C, D and the control group was ıtatîstlcally significant. On the other hand, serum PAP levels of proitate cancer cases exhibit a statistically significant difference from serum PAP levels of the control group only at stage D prostate cancer. According to these data, it is reasonable to say that P5A is a better tumor marker than-67- PAP. The difference between serum PAP and PSA levels in prostate hyperplasia cases and prostate cancer those of in stage A and B is statistically insignificant. This condition is chaotic in the detection of prostate hyperplasia and early stages of prostate cancer, The available data clearly reveal that a new parameter besides PAP and PSA is necessary to increase the efficiency in diagnosis. Serving this aim, serum sialic acid levels were investigated in the control group, prostate hyperplasia group and prostate cancer group to determine whether serum sialic acid levels are useful in diagnosis. The serum sialic acid levels determined by enzymatlc-colorimetric method were 65.75±5.59 mg/dl in the control group, 63,6±6.9 mg/dl in the hyperplasia group and 79.2819.09, 89.9B±7.D1, 92.11+12.43, 101.3+14.5 mg/dl in A, B, C and D stages respectively Df cancer group. The difference between serum sialic acid levels of the control group and the prostatic hyperplasia group was found to be statistically insignificant. However, it was demostrated that the serum sialic acid levels of cancer cases were statistically different from those of control and hyperplasia group. According to obtained data we can conclude that it is essential to determine serum sialic acid levels besides PAP and PSA in order to detect prostat cancer cases at the early stages.